Chimerix Announces Upcoming Presentations at the American Society of Clinical Oncology 2021 Annual Meeting
Chimerix (NASDAQ:CMRX), a biopharmaceutical company, announced its participation in the American Society of Clinical Oncology 2021 Annual Meeting, set for June 4-8, 2021. The company will present two oral presentations and one poster presentation, all on June 4. The oral presentations include topics on tracking tumor DNA in glioma patients and a Phase 2 study of ONC201 in neuroendocrine tumors. The poster will address a first-in-human dose escalation study of ONC206 in recurrent CNS neoplasms. Chimerix aims to develop impactful therapies for cancer and serious diseases.
- None.
- None.
DURHAM, N.C., May 19, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced upcoming oral and poster presentations at the American Society of Clinical Oncology 2021 Annual Meeting, which will be held virtually June 4-8, 2021.
Two titles have been accepted for oral presentations as follows:
Title: Serial plasma and CSF cell-free tumor DNA (cf-tDNA) tracking in diffuse midline glioma patients undergoing treatment with ONC201
Abstract Number: 2012
Date and Time: June 4, 2021 at 9:00 AM EDT
Presenter: Evan Cantor, M.D., University of Michigan
Session Title: CNS Targeting: From Delivery to Biomarker Assessment
Title: Phase 2 study of DRD2 antagonist/ClpP agonist ONC201 in neuroendocrine tumors
Abstract Number: 3002
Date and Time: June 4, 2021 from 11:00 AM - 2:00 PM EDT
Presenter: Peter M. Anderson, M.D., Ph.D., Cleveland Clinic
Session Title: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
One title has been accepted as a poster presentation as follows:
Title: First-in-human dose escalation and food effect study of oral ONC206 in adults with recurrent primary CNS neoplasms
Abstract Number: TPS2072
Date and Time: June 4, 2021 at 9:00 AM EDT
Presenter: Brett J. Theeler, M.D., Walter Reed National Military Medical Center
Session Title: Central Nervous System Tumors
About Chimerix
Chimerix is a development-stage biopharmaceutical company dedicated to accelerating the advancement of innovative medicines that make a meaningful impact in the lives of patients living with cancer and other serious diseases. Our three most advanced clinical-stage development programs are brincidofovir (BCV), ONC201 and dociparstat sodium (DSTAT). BCV is an antiviral drug candidate developed as a potential medical countermeasure for smallpox and is currently under review for regulatory approval in the United States. ONC201 is currently in a registrational clinical program for recurrent H3 K27M-mutant glioma and a blinded independent central review is expected later this year. DSTAT is in development as a potential first-line therapy in acute myeloid leukemia and as a potential treatment for acute lung injury in hospitalized COVID-19 patients.
CONTACT:
Investor Relations:
Michelle LaSpaluto
919 972-7115
ir@chimerix.com
Will O’Connor
Stern Investor Relations
212-362-1200
will@sternir.com
FAQ
What is Chimerix presenting at ASCO 2021?
When are Chimerix's presentations at the ASCO 2021 Annual Meeting?
What are the titles of the presentations by Chimerix at ASCO 2021?
Who will present for Chimerix at ASCO 2021?
What is the significance of the presentations for Chimerix (CMRX)?
